“TK216 targets microtubules in Ewing sarcoma cells.” Cell chemical biology vol. 29,8 (2022): 1325-1332.e4. doi:10.1016/j.chembiol.2022.06.002 本站内容仅用于健康知识科普,无法作为任何诊断或治疗依据,就诊请找专业医疗机构。 所有标注“原创”的文章均由'成软骨性瘤知识小站'编译整理,属于原创内容,...
TK216(临床二期); 美国TK216 in Patients With Relapsed or Refractory Ewing Sarcoma - Full Text View - ClinicalTrials.gov(在美国纽约MSK的临床实验已暂停,效果没有达到预期); 国内(似乎即将招募二期临床)A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma - Full Text Vie...
TK216 Receives Orphan Drug Designation for Ewing SarcomaNalleyCatlin
专注于开发新型肿瘤治疗方法的临床阶段生物制药公司Oncernal 公司前不久宣布,美国食品和药物管理局(FDA)已授予其TK216儿科罕见病资格认定,TK216是一种研究性潜在同类领先的肿瘤蛋白E26转化特异(ETS)家族靶向小分子抑制剂,用于治疗尤文肉瘤(Ewing sarcoma)。 根据FDA的儿科罕见病资格认定和兑换凭证计划,FDA向获得“儿科罕...
In Vitro:(-)-TK216 (compound 14; for 3 days) has an IC50<5 μM in SKES cells (Ewing Sarcoma cell line). (-)-TK216 has T1/2s of 27.7 mins, 2.8 mins, 23.1 mins and 40.8 mins for human, rat, mouse, dog liver microsomes. ...
【FDA授予TK216治疗尤文肉瘤儿科#罕见病# 资格认定 | 资讯】前不久,美国食品和药物管理局(FDA)已授予其TK216儿科罕见病资格认定,TK216是一种研究性潜在同类领先的肿瘤蛋白E26转化特异(ETS)家族靶向小分子抑制剂,用于治疗尤文肉瘤(Ewing sarcoma)。 °FDA授予TK216治疗尤文肉瘤儿科罕见病资格认定... ...
大家好,本周推荐一篇发表在Cell Chem Biol上的论文,题目为“TK216 targets microtubules in Ewing sarcoma cells”,通讯作者是来自得克萨斯大学西南医学中心的David G. McFadden教授,他的研究方向是利用基因工程和化学筛选等技术来发现癌症的...
(+)-TK216 (compound 13; for 3 days) has an IC50>5 μM in SKES cells (Ewing Sarcoma cell line). (+)-TK216 has T1/2s of 103.4 mins, 3.6 mins, 26.6 mins and 8.4 mins for human, rat, mouse, dog liver microsomes. 分子式 ...
-2-oxoethyl]-1,3-dihydro-3-hydroxy-2H-indol-2-one;2H-Indol-2-one, 4,7-dichloro-3-[2-(4-cyclopropylphenyl)-2-oxoethyl]-1,3-dihydro-3-hydroxy-;Inhibitor,EWS-FLI1,DNA/RNA Synthesis,transcription,TK-216,TK216,RNA,proliferation,EST,inhibit,sarcoma,anticancer,TK 216,leukemia,Ewing,virus,...
产品活性:(+)-TK216 是 TK216 (HY-122903) 的对映异构体。TK216 是一种口服有效的 E26 转录因子 (ETS) 抑制剂。 研究领域:Cell Cycle/DNA Damage 作用靶点:DNA/RNA Synthesis In Vitro: (+)-TK216 (compound 13; for 3 days) has an IC50>5 μM in SKES cells (Ewing Sarcoma cell line). (+...